AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7774735
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) gel
Trial: 2274632
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg to 80 mg depending on response and side effects)
Trial: 29898788
Drug: Pixatimod (PG545)
RxNorm normalized name: pidotimod
DrugBank: Pixatimod (DB19166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixatimod (PG545) administered by intravenous (IV) infusion at a dose of up to 100 mg.
Trial: 29898788
Drug: Pixatimod in
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixatimod in combination with PD-1 inhibitors (e.g., nivolumab).
Trial: 3229870
Drug: Nilvadipine 8
RxNorm normalized name: nilvadipine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 8 mg
Trial: 14621818
Drug: St. Thomas
RxNorm normalized name: St. Thomas lidpod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas Hospital (ST) solution
Trial: 4083859
Drug: Ampicillin with
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin with a lactobacillus preparation
Trial: 4083859
Drug: Ampicillin followed
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin followed 1 h later by the lactobacillus preparation
Trial: 10068928
Drug: UVA1 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVA1 therapy
Trial: 30723894
Drug: Ofatumumab 500
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 500 mg
Trial: 18437442
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 6 months
Trial: 15824254
Drug: Choline‐containing compounds,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline‐containing compounds, phosphocreatine, myo‐inositol, total N‐acetyl‐aspartate (tNAA), and glutamate‐glutamine concentrations in cortical gray matter (CGM)
Trial: 1847240
Drug: Induction combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction combination chemotherapy (ICC)
Trial: 6489410
Drug: Enprofylline 4
RxNorm normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 4 mg/kg
Trial: 6489410
Drug: Theophylline 8
RxNorm normalized name: theophylline 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 8 mg/kg
Trial: 31316682
Drug: LIPUS combined
RxNorm normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPUS combined with TENS therapy
Trial: 31316682
Drug: Only TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only TENS therapy
Trial: 22642657
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.05-0.22 U/kg)
Trial: 15971720
Drug: Neuromodulation, denervation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulation, denervation techniques, and bladder augmentation
Trial: 10583435
Drug: E2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 group (micronised oestradiol 2 mg)
Trial: 10583435
Drug: E2 +
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 + P group (E2 + trimegestone 0.5 mg)
Trial: 10583435
Drug: E2 +
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 + D group (E2 + dydrogesterone 10 mg)
Trial: 8904612
Drug: Mefloquine 250
RxNorm normalized name: mefloquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 250 mg weekly for 4 weeks
Trial: 1678925
Drug: Terazosin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin alone (1 to 80 mg/day)
Trial: 1678925
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 120 mg twice daily)
Trial: 1678925
Drug: Terazosin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (5 mg) plus methyclothiazide (2.5 to 5 mg)
Trial: 1678925
Drug: Terazosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin plus methyclothiazide (2.5 mg)
Trial: 1678925
Drug: Terazosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin plus methyclothiazide (5 mg)
Trial: 28395936
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg
Trial: 20884959
Drug: Nalmefene 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 40 mg/day
Trial: 21967071
Drug: Nalmefene 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 20 mg/day
Trial: 10811503
Drug: Eight-hour infusion
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight-hour infusion of doxorubicin (arm A)
Trial: 10811503
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of doxorubicin (arm B)
Trial: 31111801
Drug: 1-day AL
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day AL initiation regimen (ALNCD + 30 mg oral aripiprazole for 1 day)
Trial: 31111801
Drug: 21-day AL
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-day AL initiation regimen (AL + 15 mg/day of oral aripiprazole for 21 days)
Trial: 20520293
Drug: Ziprasidone (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (20-80 mg daily)
Trial: 16192477
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of total‐body irradiation (200 cGy)
Trial: 10534546
Drug: Dothiepin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (up to 150 mg daily)
Trial: 2127785
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Trial: 2127785
Drug: 1 million
RxNorm normalized name: Nystatin 1 MILLION U Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Trial: 27680013
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg monotherapy (RM)
Trial: 26359900
Drug: Deprexis (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprexis (internet-based cognitive behavioural therapy programme)
Trial: 29110574
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Therapy (MT)
Trial: 19027095
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and aspirin therapy
Trial: 14734000
Drug: F/T-PSA ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/T-PSA ratio >30% with T-PSA of 3-5.99 g/ml
Trial: 14734000
Drug: F/T-PSA ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/T-PSA ratio <10% with T-PSA of 3-5.99 g/ml
Trial: 14734000
Drug: F/T-PSA ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/T-PSA ratio >30% with T-PSA of 6-9.99 g/ml
Trial: 14734000
Drug: F/T-PSA ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/T-PSA ratio <10% with T-PSA of 6-9.99 g/ml
Trial: 9810957
Drug: Desmopressin (DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (DDAVP nasal spray)
Trial: 2647315
Drug: MQ-F-OK therapy
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MQ-F-OK therapy
Trial: 2647315
Drug: FAM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM therapy
Trial: 563620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ferrous sulfate (80 mg Fe++) and folic acid (350 microgram)
Trial: 563620
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (80 mg Fe++)
Trial: 31349916
Drug: 42-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42-day course of dexamethasone (0.5 mg/kg/day × 3 days followed by a slow taper, n=30)
Trial: 31349916
Drug: 9-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-day course of dexamethasone (0.5 mg/kg/day followed by a rapid taper, n=29)
Trial: 26472632
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive remediation with concurrent meta-cognitive skills training (CCR + MST)
Trial: 25348519
Drug: BC-3781 (pleuromutilin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC-3781 (pleuromutilin antimicrobial agent)
Trial: 9288408
Drug: Buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (10 mg)
Trial: 12881823
Drug: Threshold inspiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold inspiratory muscle trainer, twice every other day, with 3 sets of 10 loaded inspirations (40%‐60% of patients' maximal inspiratory pressure [Pimax]) over a 10‐week period
Trial: 8758084
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (3.2 mg/kg loading dose followed by 1.6 mg/kg daily)
Trial: 8758084
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine (20 mg/kg loading dose followed by 10 mg/kg every 8 h)
Trial: 1881978
Drug: Capsulated aspartame
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsulated aspartame (400 mg)
Trial: 1881978
Drug: Phenylalanine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylalanine (200 mg)
Trial: 1881978
Drug: Aspartic acid
RxNorm normalized name: Aspartic Acid
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspartic acid (200 mg)
Trial: 27009752
Drug: Western-style diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western-style diet (WD) supplemented with 2 g calcium carbonate/d for 4 weeks
Trial: 27009752
Drug: Western-style diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) for 4 weeks
Trial: 27009752
Drug: Western-style diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) and 2 g calcium carbonate/d for 4 weeks
Trial: 25551175
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message appointment reminders plus thrice-weekly supportive, informational, and motivational text messages
Trial: 20660224
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g high‐MW oat β‐glucan/d (2,210,000 g/mol)
Trial: 20660224
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g medium‐MW oat β‐glucan/d (850,000 g/mol)
Trial: 20660224
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g medium‐MW oat β‐glucan/d (530,000 g/mol)
Trial: 20660224
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g low‐MW oat β‐glucan/d (210,000 g/mol)
Trial: 18709307
Drug: Cooling by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling by frozen gel packs applied in the axilla for 5 min before treatment
Trial: 12706612
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser treatment (585 nm, 5-6 J/cm², 3 treatments at monthly intervals)
Trial: 2014075
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin regimen (increases at intervals of not less than 60 minutes)
Trial: 6804311
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 200 mg daily for 28 days
Trial: 6804311
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 400 mg daily for 28 days
Trial: 6804311
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g daily for 28 days
Trial: 26910613
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral levofloxacin (500 mg)
Trial: 19131212
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of wheat gluten hydrolysate (WGH)
Trial: 19131212
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of wheat gluten hydrolysate (WGH)
Trial: 19131212
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of wheat gluten hydrolysate (control)
Trial: 17682989
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg/day) for up to 6 months
Trial: 28291508
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg intravenous (group P, n = 30)
Trial: 7481548
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b treatment for 1 year
Trial: 1929253
Drug: Cefprozil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (500 mg once daily)
Trial: 6644347
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon treatment
Trial: 6644347
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon treatment
Trial: 27217449
Drug: Enzastaurin 500
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin 500 mg daily for 3 years
Trial: 19817718
Drug: Dexamethasone 9
RxNorm normalized name: DEXAMETHASONE 9% INTRAOCULAR SUSP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 9 mg
Trial: 7657740
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist [(imBzl)D‐His6, Pro9‐NEt]‐GnRH (D‐His) at doses of 0.01, 0.1, 1, and 10 micrograms/kg
Trial: 28236981
Drug: Tecemotide (930μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecemotide (930μg as lipopeptide) subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Trial: 28236981
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Trial: 21788267
Drug: Conventional neurological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neurological therapy
Trial: 21788267
Drug: Constraint induced
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint induced therapy
Trial: 14510624
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with negative inotropic agents (beta‐blockers, verapamil)
Trial: 11052410
Drug: Pemoline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline treatment (3 mg/kg/day, optimized dosing)
Trial: 2455109
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg b.i.d.)
Trial: 3239425
Drug: Carbachol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbachol, 150 mg subcutaneously
Trial: 3239425
Drug: Fundic distension
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fundic distension to a volume of 600 ml
Trial: 30151941
Drug: Second course
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second course of intravenous immunoglobulins (IVIg) administered 1 week after the first course
Trial: 30151941
Drug: Second course
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second course of intravenous immunoglobulins (IVIg)
Trial: 23839050
Drug: Irinotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan at dose level VI (240 mg/m²)
Trial: 23839050
Drug: Irinotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan at dose level VII (260 mg/m²)
Trial: 23839050
Drug: Irinotecan (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (overall treatment)
Trial: 21963063
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (Group A)
Trial: 16482073
Drug: ALA-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-rich diet (6.8 g/day)
Trial: 16482073
Drug: EPA/DHA-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA-rich diet (1.05 g EPA/day + 0.55 g DHA/day)
Trial: 2869950
Drug: Beta-adrenergic antagonists
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic antagonists
Trial: 11741055
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg three times a day for six weeks)
Trial: 11741055
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (800 cGy within 72 hours post-surgery)
Trial: 9438487
Drug: Loratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P)
Trial: 1397240
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment protocol
Trial: 8426204
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol
Trial: 3315542
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg daily by mouth)
Trial: 3315542
Drug: Frusemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (40 mg by mouth)
Trial: 24136330
Drug: FF/VI 200/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 200/25 μg once-daily
Trial: 24136330
Drug: FF 200
RxNorm normalized name: guaifen/pe/acetaminophen/caff 200 mg-10 mg-325 mg-32.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF 200 μg once-daily
Trial: 24136330
Drug: FP 500
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 500 μg twice-daily
Trial: 20026784
Drug: Torcetrapib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib (60 mg)
Trial: 12649629
Drug: Once-daily OROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily OROS methylphenidate (OROS MPH)
Trial: 11000370
Drug: Lifting of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifting of the abdominal wall (L)
Trial: 2427840
Drug: Celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 200 mg daily for 2 weeks, then 400 mg daily for 2 weeks, and 600 mg daily for another 2 weeks for non-responders
Trial: 18412271
Drug: Combined PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined PCI and optimal medical therapy (OMT)
Trial: 10385633
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg daily for 5 weeks
Trial: 1997850
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 to 0 mg per day for 8 days)
Trial: 30321201
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy including desensitization manoeuvres of the central nervous system (n = 60)
Trial: 26725717
Drug: Point prevalence
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point prevalence of vaccine types HPV‐6,‐11,‐16, and ‐18
Trial: 21992596
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day S‐(‐)equol for 12 weeks
Trial: 15810623
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg bid